The RNF6 (Ring Finger Protein 6) antibody is a tool used to study the RNF6 protein, an E3 ubiquitin ligase belonging to the RING finger protein family. RNF6 plays a key role in the ubiquitin-proteasome system, regulating protein degradation by tagging substrates with ubiquitin molecules. It is involved in diverse biological processes, including cell proliferation, apoptosis, and signal transduction. Research highlights its role in cancer progression, particularly in hormone-dependent cancers like prostate and breast cancer, where RNF6 overexpression has been linked to tumor growth, metastasis, and therapy resistance by modulating pathways such as the androgen receptor (AR) signaling axis.
The RNF6 antibody is widely utilized in techniques like Western blotting, immunohistochemistry (IHC), and immunoprecipitation (IP) to detect RNF6 expression levels, localization, and interactions in cells or tissues. Studies using this antibody have revealed elevated RNF6 levels in multiple cancers, correlating with poor prognosis. Structurally, RNF6 contains a characteristic RING domain critical for its E3 ligase activity and a C-terminal region involved in substrate recognition. Antibodies targeting specific epitopes help dissect its functional domains and post-translational modifications.
Recent work also implicates RNF6 in neurodegenerative diseases, where dysregulated ubiquitination may contribute to protein aggregation. The antibody thus serves as a vital reagent for exploring RNF6's dual roles in oncology and neurology, aiding therapeutic targeting and mechanistic studies.